The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications

Simple item page
dc.contributor.authorAurilio, Gaetano
dc.contributor.authorPiva, Francesco
dc.contributor.authorSantoni, Matteo
dc.contributor.authorCimadamore, Alessia
dc.contributor.authorSorgentoni, Giulia
dc.contributor.authorLopez-Beltran, Antonio
dc.contributor.authorCheng, Liang
dc.contributor.authorBattelli, Nicola
dc.contributor.authorNolè, Franco
dc.contributor.authorMontironi, Rodolfo
dc.contributor.departmentPathology and Laboratory Medicine, School of Medicineen_US
dc.date.accessioned2020-03-20T15:53:18Z
dc.date.available2020-03-20T15:53:18Z
dc.date.issued2019-11-13
dc.description.abstractObesity is a well-known risk factor for renal cell carcinoma (RCC) development. However, the RCC–obesity link has not been fully addressed when considering a comprehensive scenario starting from pathogenetic aspects through pathological issues up to the outcome of medical treatment. We therefore conducted an electronic PubMed search using keywords “obesity”, “body mass index”, “overweight”, “renal cell carcinoma/kidney cancer”, “medical treatment”, “targeted therapy”, and “immunotherapy/immune checkpoint inhibitors”. The selected data supported a crosstalk between adipose tissue (adipocytes and other white adipose tissue cells) and cancer cells inducing several signaling pathways that finally stimulated angiogenesis, survival, and cellular proliferation. Accurate sampling of renal sinus fat correlated with a prognostic value. Retrospective clinical evidence in metastatic RCC patients with higher body mass index (BMI) and treated with targeted therapies and/or immune checkpoint inhibitors showed advantageous survival outcomes. Therefore, obesity may influence the course of RCC patients, although the interplay between obesity/BMI and RCC warrants a large prospective confirmation. We are therefore still far from determining a clear role of obesity as a prognostic/predictive factor in metastatic RCC patients undergoing targeted therapy and immunotherapy.en_US
dc.identifier.citationAurilio, G., Piva, F., Santoni, M., Cimadamore, A., Sorgentoni, G., Lopez-Beltran, A., ... & Montironi, R. (2019). The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications. International journal of molecular sciences, 20(22), 5683. 10.3390/ijms20225683en_US
dc.identifier.urihttps://hdl.handle.net/1805/22391
dc.language.isoen_USen_US
dc.publisherMDPIen_US
dc.relation.isversionof10.3390/ijms20225683en_US
dc.relation.journalInternational Journal of Molecular Sciencesen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourcePMCen_US
dc.subjectObesityen_US
dc.subjectBody mass indexen_US
dc.subjectRenal cell carcinomaen_US
dc.subjectTargeted therapyen_US
dc.subjectImmunotherapyen_US
dc.subjectClinical outcomesen_US
dc.titleThe Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implicationsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijms-20-05683.pdf
Size:
765.23 KB
Format:
Adobe Portable Document Format
Description:
Main article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Pathology and Laboratory Medicine Works